量研学術機関リポジトリ「QST-Repository」は、国立研究開発法人 量子科学技術研究開発機構に所属する職員等が生み出した学術成果（学会誌発表論文、学会発表、研究開発報告書、特許等）を集積しインターネット上で広く公開するサービスです。 Welcome to QST-Repository where we accumulates and discloses the academic research results(Journal Publications, Conference presentation, Research and Development Report, Patent, etc.) of the members of National Institutes for Quantum Science and Technology.
Thank you very much for using our website. On the 11th of March 2019, this site was moved from our own network server to the JAIRO Cloud network server. If you previously bookmarked this site, that bookmark will no longer work. We would be grateful if you could bookmark the website again. Thank you very much for your understanding and cooperation.
ObjectivesFDG-PET provides quantitative information regarding the tumor glucosemetabolism which is useful for the clinical diagnosis of tumor diseases. Adiffusion weighted image (DWI) by MRI can be useful in detecting malignanciessimilar to FDG-PET imaging. We evaluated the role of the clinical use ofFDG-PET/CT and DWI by MRI in the differential diagnosis of tumor malignancywith suspected pancreatic cancer, and in the prediction of tumor recurrence forpancreatic cancer. Materials and Methods Pre-surgery patients with eitherproven or suspected primary pancreatic cancer underwent a whole body FDG-PET/CTand DWI by MRI. The malignancy or benignancy of excised specimens waspathologically confirmed in all cases. The tumor glucose metabolism wasevaluated with standardized uptake value (SUV) in FDG-PET/CT (Aquiduo; Toshiba)study. After at least 6hours of fasting, each patient was injected with FDG(217.8-372.5MBq, average: 321.6MBq ) 60 min before imaging. DWI acquired with a3.0-T MRI scanner (Signa HDx 3T; GE Healthcare) with an 8 channel TORSO arraycoil (8US TORSOPA). The apparent diffusion coefficient (ADC) were measured withDWI using a spin echo echo-planar sequence, TR=10s; TE=80 ms; b value=400, 800,1200s/mm2. We obtained SUV from the FDG injected dose and patientbody weight, and ADC from DWI with three types of b values. ADC was calculatedusing the Advantage work station 4.2; fanctool2, GE Healthcare, and we used theaverage values for ADC value. The value of each factor for differentialdiagnosis of tumor malignancy was determined by analysis of the area under thereceiver operating characteristic (ROC) curve with suspected pancreatic cancer.Similarly, the predictive value of each factor for 1-year tumor recurrence wasdetermined by analysis of the area under the ROC curve with proven pancreaticcancer. Results On ROC curve analysis for differential diagnosis of tumormalignancy, the areas under the curve of SUV and ADC were 0.855 and 0.830,respectively. On ROC curve analysis for tumor recurrence, the areas under thecurve of SUV and ADC were 0.843 and 0.600, respectively. The 1-year recurrencefree survival rate above the cutoff (SUV>4.3) was markedly different fromthe rate below the cutoff (SUV≤4.3) (100% vs. 67%, p<0.01). ConclusionsFDG-PET/CT and ADC from MRI are helpful in differential diagnosis of tumormalignancy. FDG-PET/CT should be performed in preoperative evaluation ofpancreatic tumor not only for differential diagnosis of tumor malignancy butalso for prediction of tumor recurrence.
Prediction of tumor recurrence by FDG-PET/CT and MRI for pancreatic cancer
